Lipids and Cerebrovascular Disease: Research and Practice

Stroke

Volumn 46, Issue 11, 2015, Pages 3322-3328

  Yaghi, Shadi ^a   Elkind, Mitchell S V ^b  

^a BROWN UNIVERSITY   (United States)

^b Columbia University ^*  (United States)

Author keywords

cerebral hemorrhage; cholesterol; lipids; lipoprotein(a); stroke

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE;

BRAIN DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; HUMAN; LIPID ANALYSIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; WHITE MATTER DISEASE; BLOOD; CEREBRAL HEMORRHAGE; DYSLIPIDEMIAS; LEUKOENCEPHALOPATHIES; STROKE;

BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; EZETIMIBE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LEUKOENCEPHALOPATHIES; LIPOPROTEIN(A); PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; SECONDARY PREVENTION; STROKE; TRIGLYCERIDES;

EID: 84945974488     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011164     Document Type: Review

References (60)

1. Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP, Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 1999 30 2535 2540
2. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, Asia Pacific Cohort Studies Collaboration Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003 32 563 572
3. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM, Lipid levels and the risk of ischemic stroke in women. Neurology 2007 68 556 562. doi: 10.1212/01.wnl.0000254472.41810.0d
4. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de Concalves A, Inzitari D, Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health 2002 56 Suppl 1 i19 i24
5. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Atherosclerosis Risk in Communities Study Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003 34 623 631. doi: 10.1161/01.STR.0000057812.51734.FF
6. Horenstein RB, Smith DE, Mosca L, Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002 33 1863 1868
7. Lindenstrøm E, Boysen G, Nyboe J, Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994 309 11 15
8. Sacco RL, Benson RT, Kargman DE, Boden-Albala B, Tuck C, Lin IF, High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001 285 2729 2735
9. Psaty BM, Anderson M, Kronmal RA, Tracy RP, Orchard T, Fried LP, The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. J Am Geriatr Soc 2004 52 1639 1647. doi: 10.1111/j.1532-5415.2004.52455.x
10. Bowman TS, Sesso HD, Ma J, Kurth T, Kase CS, Stampfer MJ, Cholesterol and the risk of ischemic stroke. Stroke 2003 34 2930 2934. doi: 10.1161/01.STR.0000102171.91292.DC
11. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG, Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008 300 2142 2152. doi: 10.1001/jama.2008.621
12. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007 298 309 316. doi: 10.1001/jama.298.3.309
13. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD, Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989 320 904 910. doi: 10.1056/NEJM198904063201405
14. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ, Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet 2001 357 922 925. doi: 10.1016/S0140-6736(00)04213-6
15. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M, Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 2007 38 2718 2725. doi: 10.1161/STROKEAHA.107.487090
16. Bonaventure A, Kurth T, Pico F, Barberger-Gateau P, Ritchie K, Stapf C, Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2010 210 243 248. doi: 10.1016/j.atherosclerosis.2009.10.043
17. Wieberdink RG, Poels MM, Vernooij MW, Koudstaal PJ, Hofman A, van der Lugt A, Serum lipid levels and the risk of intracerebral hemorrhage: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2011 31 2982 2989. doi: 10.1161/ATVBAHA.111.234948
18. Wang X, Dong Y, Qi X, Huang C, Hou L, Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke 2013 44 1833 1839. doi: 10.1161/STROKEAHA.113.001326
19. Chrostek L, Supronowicz L, Panasiuk A, Cylwik B, Gruszewska E, Flisiak R, The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med 2014 14 417 421. doi: 10.1007/s10238-013-0262-5
20. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A, Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann Clin Lab Sci 2007 37 343 348
21. Amarenco P, Labreuche J, Touboul PJ, High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008 196 489 496. doi: 10.1016/j.atherosclerosis.2007.07.033
22. Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 370 153 160. doi: 10.1016/S0140-6736(07)61088-5
23. Tiozzo E, Gardener H, Hudson BI, Dong C, Della-Morte D, Crisby M, High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan Study. Atherosclerosis 2014 237 163 168. doi: 10.1016/j.atherosclerosis.2014.09.002
24. Chei CL, Yamagishi K, Kitamura A, Kiyama M, Imano H, Ohira T, CIRCS Investigators High-density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population: the Circulatory Risk in Communities Study. Stroke 2013 44 327 333. doi: 10.1161/STROKEAHA.112.674812
25. Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P, Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: systematic review and meta-regression analysis. Atherosclerosis 2010 212 9 15. doi: 10.1016/j.atherosclerosis.2010.02.011
26. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R, Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1996 16 471 478
27. Ridker PM, Stampfer MJ, Hennekens CH, Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995 273 1269 1273
28. Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012 32 3058 3065. doi: 10.1161/ATVBAHA.112.255521
29. Ohira T, Schreiner PJ, Morrisett JD, Chambless LE, Rosamond WD, Folsom AR, Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006 37 1407 1412. doi: 10.1161/01.STR.0000222666.21482.b6
30. Boden-Albala B, Kargman DE, Lin IF, Paik MC, Sacco RL, Berglund L, Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovasc Dis 2010 30 237 243. doi: 10.1159/000319065
31. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM, Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004 63 1868 1875
32. Cui R, Iso H, Yamagishi K, Saito I, Kokubo Y, Inoue M, JPHC Study Group High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study. Atherosclerosis 2012 221 565 569. doi: 10.1016/j.atherosclerosis.2012.01.013
33. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2009 40 382 388. doi: 10.1161/STROKEAHA.108.529537
34. Amarenco P, Labreuche J, Elbaz A, Touboul PJ, Driss F, Jaillard A, GENIC Investigators Blood lipids in brain infarction subtypes. Cerebrovasc Dis 2006 22 101 108. doi: 10.1159/000093237
35. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D'Agostino RB, Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004 35 1857 1861. doi: 10.1161/01.STR.0000135226.53499.85
36. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, Lefkowitz D, Jungreis C, Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005 36 56 61. doi: 10.1161/01.STR.0000149625.99732.69
37. Jimenez-Conde J, Biffi A, Rahman R, Kanakis A, Butler C, Sonni S, Hyperlipidemia and reduced white matter hyperintensity volume in patients with ischemic stroke. Stroke 2010 41 437 442. doi: 10.1161/STROKEAHA.109.563502
38. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008 70 1208 1214. doi: 10.1212/01.wnl.0000307750.41970.d9
39. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014 45 2160 2236. doi: 10.1161/STR.0000000000000024
40. Friedewald WT, Levy RI, Fredrickson DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 499 502
41. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010 56 977 986. doi: 10.1373/clinchem.2009.142810
42. Kargman DE, Tuck C, Berglund L, Lin IF, Mukherjee RS, Thompson EV, Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis 1998 139 391 399
43. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Major lipids, apolipoproteins, and risk of vascular disease. Jama 2009 302 1993 2000
44. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 63 25 pt B 2889 2934. doi: 10.1016/j.jacc.2013.11.002
45. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 7 22
46. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Efficacy and safety of more intensive lowering of ldl cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 376 1670 1681
47. Amarenco P, Labreuche J, Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009 8 453 463. doi: 10.1016/S1474-4422(09)70058-4
48. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006 355 549 559. doi: 10.1056/NEJMoa061894
49. Lackland DT, Elkind MS, D'Agostino R Sr, Dhamoon MS, Goff DC Jr, Higashida RT, American Heart Association Stroke Council; Council on Epidemiology and Prevention; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012 43 1998 2027. doi: 10.1161/STR.0b013e31825bcdac
50. Elkind MS, Sacco RL, MacArthur RB, Fink DJ, Peerschke E, Andrews H, The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int J Stroke 2008 3 210 218. doi: 10.1111/j.1747-4949.2008.00200.x
51. Lavigne PM, Karas RH, The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013 61 440 446. doi: 10.1016/j.jacc.2012.10.030
52. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, VA-HIT Study Group Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001 103 2828 2833
53. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010 375 1875 1884. doi: 10.1016/S0140-6736(10)60656-3
54. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, IMPROVE-IT Investigators Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015 372 2387 2397. doi: 10.1056/NEJMoa1410489
55. De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A, Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010 55 198 211. doi: 10.1016/j.jacc.2009.07.062
56. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA, Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012 59 2344 2353. doi: 10.1016/j.jacc.2012.03.007
57. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med 2015 163 40 51. doi: 10.7326/M14-2957
58. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, ODYSSEY LONG TERM Investigators Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1489 1499. doi: 10.1056/NEJMoa1501031
59. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015 372 1500 1509. doi: 10.1056/NEJMoa1500858
60. McKinney JS, Kostis WJ, Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke 2012 43 2149 2156. doi: 10.1161/STROKEAHA.112.655894